Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance Nivolumab vs Observation in Intermediate Risk HPV+ OPSCC
NCT03811015Phase 3Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Aug 2019
- Primary completion
- Jan 2030
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nivolumab in oropharyngeal squamous cell carcinoma (OPSCC) (3 arms), sponsored by National Cancer Institute. Primary endpoints: Overall Survival at 10 years, Negative 12 week post therapy FDG PET/CT associated with OS and 1 more. Started Aug 2019; status: active, not recruiting.
02
Drugs
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on NCT03811015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03811015.